Health Research Group Publications
Founded in 1971 by Sidney Wolfe, M.D. and Ralph Nader, Public Citizen’s Health Research Group promotes research-based, system-wide changes in health-care policy and drug safety. The work that we have done since 1995 is listed on this page in chronological order.
Public Citizen published an article on Other98.com that outlines the true causes for high drug prices in the U.S. and makes the case for why consumers should rally behind the recently introduced Affordable Meds Act to rein in monopoly abuses by Big Pharma and make medicines affordable.
In a letter to the editor of The Hill, Public Citizen criticized a recent op-ed (“Beryllium broadside: Obama’s last-minute rule-making will cost jobs”) for unfairly decrying the U.S. Occupational Safety and Health Administration’s (OSHA’s) efforts to protect workers from exposure to beryllium in the workplace.
In comments to the Food and Drug Administration (FDA) on manufacturer communications regarding unapproved uses of approved or cleared medical products, Public Citizen discusses the risks to patients when manufacturers promote their products for unapproved uses and the unreliability of journal articles as a basis for physicians’ decisionmaking. We also explain that the First Amendment does not support the industry call for relaxation of the restrictions on promoting products for uses that the FDA has not approved as safe and effective for patients.
Public Citizen expressed serious concern regarding the Food and Drug Administration’s (FDA’s) failure to provide timely notice in the Federal Register of the April 13, 2017, meeting of the Antimicrobial Drugs Advisory Committee in accordance with the requirements of the agency’s own regulations. In the event that the agency fails to provide timely notice of advisory committee meetings in accordance with all regulatory requirements with respect to future advisory committee meetings, we will pursue available legal avenues to ensure compliance.
Dr. Gottlieb’s appointment as FDA Commissioner would further accelerate a decades-long trend in which agency leadership too often makes decisions that are aligned more with the interests of industry than those of patients. We urge other senators to oppose Dr. Gottlieb’s nomination. The Senate should demand a nominee who is better suited to protect public health, rather than a venture capitalist who is ridden with conflicts of interest.
In testimony before a joint meeting of the Food and Drug Administration’s Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees, Public Citizen concludes that the risks of reformulated Opana ER (extended release oxymorphone) outweigh its benefits and recommends that the drug be withdrawn from the market.
Public Citizen filed comments urging the Occupational Safety and Health Administration (OSHA) to reject a proposal to delay the effective date of its final beryllium rule. The proposal would postpone the effective date of the rule by 60 days, from the current date of March 21, 2017 to May 20, 2017, and would therefore put workers’ lives at risk.
Dr. Scott Gottlieb, President Trump’s pick to be Commissioner of the Food and Drug Administration (FDA), is entangled in an unprecedented web of Big Pharma ties. He has spent most of his career dedicated to promoting the financial interests of the pharmaceutical industry, and the U.S. Senate must reject him.
The ACGME announced that effective July 1, 2017, it has rescinded the current 16-hour shift limit for first-year medical residents (also known as interns) and will allow them to work 28-hour or longer shifts without sleep.
Public Citizen sent a letter to members of Congress urging them to oppose three bills with various names — S. 204, H.R. 878 and H.R. 1020 —that would most appropriately each be titled the “False Hope Act of 2017.” These bills provide false hope to patients and are related to a nationwide lobbying effort funded by the Goldwater Institute, which has deceptively branded such laws as “Right to Try” legislation. The legislation would put countless patients at risk by dramatically undermining the FDA’s role in ensuring that medical products are safe and effective before they become widely used.